03:26 , Jun 3, 2017 |  BioCentury  |  Product Development

Leading with lung

Lung cancer squeezed past breast cancer as the top indication at the American Society of Clinical Oncology meeting this year as targeted therapies duke it out within genetically defined subgroups, while immunotherapies seek their best...
23:04 , Mar 7, 2017 |  BC Week In Review  |  Company News

AZ, Sanofi deal

The MedImmune LLC unit of AstraZeneca and Sanofi’s Sanofi Pasteur vaccines unit partnered to develop and commercialize MedImmune's MEDI8897. AZ will continue development of MEDI8897 until its first approval and is responsible for manufacturing. Sanofi...
17:43 , Mar 3, 2017 |  BC Extra  |  Company News

AZ, Sanofi sharing rights to infant RSV prophylaxis

The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) and the Sanofi Pasteur vaccines unit of Sanofi (Euronext:SAN; NYSE:SNY) said they will share rights to develop and commercialize infant respiratory syncytial virus (RSV) therapeutic MEDI8897....
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

RSV mAb regulatory update

AstraZeneca’s MedImmune LLC unit said FDA granted Fast Track designation to MEDI8897 to prevent lower respiratory tract infection caused by respiratory syncytial virus (RSV) in infants and young children. The human IgG1 kappa...
08:00 , Jan 8, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Fused bispecific antibodies

Drug platforms TECHNOLOGY: Antibody scaffolds Cell culture and mouse studies suggest chemical and enzymatic coupling of two full-sized blocking antibodies at their carboxy termini could produce bispecific molecules that retain full activity against both targets. In vitro,...
08:00 , Nov 14, 2013 |  BC Innovations  |  Targets & Mechanisms

RSVing for site zero

Despite decades of research, respiratory syncytial virus (RSV) remains a highly prevalent childhood pathogen without an approved vaccine.1 There is a marketed prophylactic-Synagis palivizumab-to prevent severe disease caused by RSV in at-risk infants, but the...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Company News

AIMM Therapeutics, Cosmo Pharmaceuticals S.p.A. deal

AIMM Therapeutics B.V., Amsterdam, the Netherlands   Cosmo Pharmaceuticals S.p.A. (SIX:COPN), Lainate, Italy   Business: Gastrointestinal, Cancer   AIMM and Cosmo partnered to develop oral diagnostic and therapeutic antibodies for gastrointestinal diseases, including colon carcinoma. Cosmo will use...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

AIMM Therapeutics management update

AIMM Therapeutics B.V., Amsterdam, the Netherlands   Business: Infectious, Antibodies   Hired: Jan de Vries as CEO, formerly head of the Novartis Research Institutes for Biomedical Research and global head of autoimmunity, transplantation and inflammation at ...
08:00 , Jan 21, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms mAb-producing, immortalized memory B cells A method to isolate and immortalize antibody-producing memory B...
08:00 , Jan 14, 2010 |  BC Innovations  |  Tools & Techniques

Making mAbs en masse

A primary goal for antibody makers is capturing the full diversity of mAbs generated by the human immune system, then isolating and cloning individual memory cells that produce mAbs against a particular antigen. But harnessing...